There are currently 51 active clinical trials seeking participants for Rheumatoid Arthritis research studies. The states with the highest number of trials for Rheumatoid Arthritis participants are Florida, California, Texas and Pennsylvania.
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
NCT04751396
Recruiting
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis, Enteropathic Arthritis, Enteropathic Spondylitis
Register for Updates
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
NCT05787821
Recruiting
The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2024
Locations: Denver Hip & Knee, Inc., Parker, Colorado +16 locations
Conditions: Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis
Register for Updates
RA-PRO PRAGMATIC TRIAL
NCT04692493
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2024
Locations: East Alabama Arthritis Center PC, Auburn, Alabama +48 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Rheumatoid Arthritis Shared Decision Making
NCT05530694
Recruiting
Shared decision making is the first overarching principle for the treat to target guidelines for rheumatoid arthritis (RA) and has been proposed as a potential mechanism to reduce health disparities, however there is little evidence to inform effective ways to implement this practice in the care of Veterans with RA. The purpose of this project is to evaluate the effectiveness of a multi-component shared decision making intervention on RA disease activity, adherence to RA medications and patient... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2024
Locations: San Francisco VA Medical Center, San Francisco, CA, San Francisco, California +3 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT03414502
Recruiting
This is a 16-week, open-label study to identify factors that help predict clinical responses to disease-modifying antirheumatic drugs (DMARD) therapies for rheumatoid arthritis (RA) patients. All patients will receive a starting dose of DMARD medication(s) which may be adjusted by the investigator as needed. If a subject becomes intolerant to a DMARD medication the subject will be withdrawn from the study at the discretion of the investigator. Visits (prior to week 16) where withdrawal is determ... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
09/12/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Rheumatoid Arthritis
Register for Updates
Early Rheumatoid Arthritis Lung Disease Study
NCT03192267
Recruiting
The primary goal of this study is to investigate lung disease, through pulmonary function and high resolution chest CT, in newly diagnosed rheumatoid arthritis (RA) patients. Extra-articular disease occurs in approximately 50% of RA patients, with the lung being a common site of involvement. Investigators goal is to understand the prevalence of lung disease in early RA patients and to better characterize it through questionnaires, imaging, and serum studies. Additionally, the goal is to find no... Read More
Gender:
ALL
Ages:
Between 19 years and 90 years
Trial Updated:
09/12/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Rheumatoid Arthritis
Register for Updates
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
NCT06581562
Recruiting
This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris (PV), Granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA) as a therapeutic, or is recommended (e.g., in Systemic Lupus Erythematosus (SLE) as a cornerstone for disease management.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: IRIS Research and Development, LLC, Plantation, Florida
Conditions: Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
Register for Updates
CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry
NCT01402661
Recruiting
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for RA in a cohort of patients cared for by rheumatologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2024
Locations: CorEvitas, LLC, Waltham, Massachusetts
Conditions: Rheumatoid Arthritis
Register for Updates
2-HOBA Phase 2 Clinical Trial in Rheumatoid Arthritis
NCT05274243
Recruiting
This is a phase 2 study to determine 2-HOBA's tolerability, safety, and effect on isoLG-adducts in patients with rheumatoid arthritis (RA) patients. Up to 32 subjects will be randomized to 750mg 2-HOBA or matching placebo three times a day for 4 weeks. As primary outcome measures investigators will compare tolerability and adverse events and changes in isoLG adducts in active and placebo arms. Among prespecified exploratory outcomes investigators will compare changes in markers of inflammation,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Rheumatoid Arthritis
Register for Updates
Pain Processing in Inflammatory and Non-Inflammatory Chronic Pain Syndromes
NCT05277025
Recruiting
Fibromyalgia (FM) is a chronic musculoskeletal pain disorder that afflicts up to 4% of the general population. The evaluation of pain mechanisms in FM has shown predominant central abnormalities and therefore has been designated as nociplastic pain syndrome. Rheumatoid arthritis (RA) is characterized by polyarthritis and pain from inflamed tissues, consistent with nociceptive pain. FM and RA patients may utilize overlapping pain mechanisms resulting in nociceptive and nociplastic pain.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/14/2024
Locations: University of Florida, Gainesville, Florida
Conditions: Fibromyalgia, Rheumatoid Arthritis
Register for Updates
ConsideRAte Study - Splenic Stimulation for RA
NCT05003310
Recruiting
This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. The study will consist of 4 study periods, including a Randomized Control Trial period (Period 1), an Open Label period (Period 2), a Treat-to-target period (Period 3), and a Long-term Follow-up period (Period 4). Participants eligible for implant will have active r... Read More
Gender:
All
Ages:
Between 22 years and 75 years
Trial Updated:
05/20/2024
Locations: Pinnacle Research Group, LLC, Anniston, Alabama +13 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
NCT04748809
Recruiting
In a previous exploratory study, the investigators observed an effect on disease activity outcomes of anti-inflammatory diet. The investigators also observed change in microbiome and circulating metabolites. The current study will determine whether or not the addition of anti-inflammatory diet improves the clinical outcomes in participants with rheumatoid arthritis, and the role of microbiome and circulating metabolites.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: UCSD, La Jolla, California
Conditions: Rheumatoid Arthritis
Register for Updates